Inmunotek invests a large percentage of its income in R&D.
Its R&D team comprises top researchers who work on various technological development, innovation and research projects. The R&D department has well equipped labs of proteomics, molecular biology and immunology.
Inmunotek R&D lines focus on allergy and immunology (allergens, immunotherapy, immunomodulators, tumor markers, cancer vaccines) and on the development of IT tools for clinical applications.
Our motto, Innovating and Sharing Ideas, represents our focus on dynamic research open to cooperation with other groups and companies.
At present, Inmunotek is involved in several active projects with researchers from the School of Medicine and Chemistry (Madrid Complutense University), San Carlos Hospital and Gregorio Marañon Hospital (Madrid), Salamanca University, Spanish National Center for Cardiovascular Research (CNIC) and the Instituto de Salud Carlos III (ISCIII).
Inmunotek was also engaged as a member of the ViVac European consortium project (7th Framework Program) together with institutions from Sweden (Vicogel AB) and Norway (Lytix Biopharma), with the cooperation of the Karolinska Institute (Sweden), the Norwegian University of Science and Technology (Norway) and Hacettepe University (Turkey). Other research projects were performed with the University of Barranquilla (Colombia) and the King Faisal Hospital & Research Centre (South Arabia).